Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 4/20 | 0.65 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | RARB | P10826 | 1/20 | 0.40 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.37 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.37 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10106324 | 0.99 | FDFT1 (0.67) | FDFT1HTR2AGRM2RARBPRKAG1 | |
| SCHEMBL414482 | 0.98 | FDFT1 (0.65) | FDFT1HTR2AGRM2RARBPRKAG1 | |
| Potassium Ion SCHEMBL414483 | 0.79 | FDFT1 (1.00) | FDFT1 | |
| SCHEMBL8624000 | 0.77 | FDFT1 (0.44) | FDFT1 | |
| SCHEMBL23752399 | 0.76 | FDFT1 (0.60) | FDFT1 | |
| SCHEMBL8946999 | 0.76 | FDFT1 (0.60) | FDFT1 | |
| SCHEMBL8621199 | 0.76 | FDFT1 (0.60) | FDFT1 | |
| SCHEMBL8619964 | 0.75 | FDFT1 (0.61) | FDFT1RARB | |
| SCHEMBL8618477 | 0.75 | FDFT1 (0.46) | FDFT1 | |
| SCHEMBL1237801 | 0.75 | FDFT1 (0.61) | FDFT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022024-A1 | ANTI-BACTERIAL COMPOSITIONS AND METHODS INCLUDING TARGETING VIRULENCE FACTORS OF STAPHYLOCOCCUS AUREUS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2010123599-A9 | ANTI-BACTERIAL COMPOSITIONS AND METHODS INCLUDING TARGETING VIRULENCE FACTORS OF STAPHYLOCOCCUS AUREUS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-02-17 | — | — | WO | disclosed |
| WO-2010123599-A2 | ANTI-BACTERIAL COMPOSITIONS AND METHODS INCLUDING TARGETING VIRULENCE FACTORS OF STAPHYLOCOCCUS AUREUS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022024-A1 | ANTI-BACTERIAL COMPOSITIONS AND METHODS INCLUDING TARGETING VIRULENCE FACTORS OF STAPHYLOCOCCUS AUREUS | CUTA, MMP8, CLPP | FDFT1 1987/4885HTR2A 4739/4885GRM2 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.